Výsledky vyhledávání - Erika Hamilton

Upřesnit hledání
  1. 1
    Targeting CDK4/6 in patients with cancer

    Targeting CDK4/6 in patients with cancer Autor Erika Hamilton, Jeffrey R. Infante

    Vydáno 2016
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Targeting HER2-positive breast cancer: advances and future directions

    Targeting HER2-positive breast cancer: advances and future directions Autor Sandra M. Swain, Mythili Shastry, Erika Hamilton

    Vydáno 2022
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

    Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer Autor Mythili Shastry, Saya Jacob, Hope S. Rugo, Erika Hamilton

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

    PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer Autor Erika Hamilton, Rinath Jeselsohn, Linda T. Vahdat, Sara A. Hurvitz

    Vydáno 2025
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role

    Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging... Autor Maxwell R. Lloyd, Seth A. Wander, Erika Hamilton, Pedram Razavi, Aditya Bardia

    Vydáno 2022
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Rise of Antibody-Drug Conjugates: The Present and Future

    Rise of Antibody-Drug Conjugates: The Present and Future Autor Mythili Shastry, Avantika Gupta, Sarat Chandarlapaty, Matthew R. Young, Thomas Powles, Erika Hamilton

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

    Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity Autor Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis, Garry Weems, Laura Carter, Xiao Hu, Marshall T. Schreeder, H. Jeffrey Wilkins

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HE... Autor Erika Hamilton, Javier Cortés, Özgür Özyılkan, Shin‐Cheh Chen, Katarína Petráková, Alexey Manikhas, Guy Jérusalem, Roberto Hegg, Jens Huober, Wei Zhang, Yanyun Chen, Miguel Martín

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

    Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing Autor Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith O. Hopkins, Gretchen Kimmick, Justin Favaro, Erika Hamilton, Renee Welch, Sarah Bacus, Kimberly Blackwell

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

    Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes Autor Timothy A. Yap, Erika Hamilton, Todd M. Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, Aaron Enke, Sabrina Hurley, Kevin K. Lin, Jenn Habeck, Heidi Giordano, Geoffrey I. Shapiro

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

    Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up Autor Sylvia Adams, Jennifer R. Diamond, Erika Hamilton, Paula R. Pohlmann, Sara M. Tolaney, Ching‐Wei Chang, Wei Zhang, Koho Iizuka, Paul Foster, Luciana Molinero, Roel Funke, John D. Powderly

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer Autor Mark D. Pegram, Erika Hamilton, Antoinette R. Tan, Anna Maria Storniolo, Kemal Balic, Anton I. Rosenbaum, Meina Liang, Peng He, Shannon Marshall, Anita Scheuber, Mayukh Das, Manish R. Patel

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

    A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer Autor Erika Hamilton, Manish R. Patel, Anne Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah Morgan, Gaia Schiavon, Hazel M. Weir, Seock‐Ah Im

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer

    273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer Autor Erika Hamilton, Javier Cortés, Özgür Özyılkan, S-C. Chen, Katarína Petráková, Alexey Manikhas, Guy Jérusalem, Roberto Hegg, Jens Huober, Sonya C. Chapman, Zhengyu Yang, Yongmei Chen, Erica L. Johnston, Miguel Martín

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

    The evolution of cyclin dependent kinase inhibitors in the treatment of cancer Autor Komal Jhaveri, Howard A Burris rd, Timothy A. Yap, Erika Hamilton, Hope S. Rugo, Jonathan W. Goldman, Stephen G. Dann, Feng Liu, Gilbert Y. Wong, Heike I. Krupka, Geoffrey I. Shapiro

    Vydáno 2021
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  16. 16
    185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)

    185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in... Autor C. Anders, S. Loi, Erika Hamilton, Komal Jhaveri, P. Schmid, Erhan Gökmen, S-A. Im, Cengiz Karaçin, Carlos H. Barrios, Y.H. Park, S. Uzunoğlu, Sarah E. Boston, Adam Konpa, S. Mondal, Fabrice André

    Vydáno 2024
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

    PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors Autor Timothy A. Yap, Atish D. Choudhury, Erika Hamilton, Lee S. Rosen, Kayla Stratton, M. Gordon, David Schaer, Lei Liu, L. Zhang, Rajendar K. Mittapalli, Wei Zhong, N. Soman, A. W. Tolcher

    Vydáno 2024
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

    Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion Autor Erika Hamilton, Kimberly Blackwell, Amy Hobeika, Timothy M. Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frédéric Lehmann, Neil L. Spector, Jun-Ping Wei, Takuya Osada, H. Kim Lyerly

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Autor Siqing Fu, Bradley R. Corr, Kerry Culm-Merdek, Colleen Mockbee, Hagop Youssoufian, Robert Stagg, R. Wendel Naumann, Robert M. Wenham, Rafael D. Rosengarten, Laura E. Benjamin, Erika Hamilton, Kathleen N. Moore

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer

    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer Autor Nehal J. Lakhani, Daphne Stewart, Debra L. Richardson, Lauren Dockery, Linda Van Le, Justin Call, Fatima Rangwala, Guanfang Wang, Bo Ma, Simon Metenou, Jade Huguet, Elliot Offman, Lini Pandite, Erika Hamilton

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: